Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Gout drug Colchicine to be tested as COVID-19 treatment in UK trial

11/27/2020 | 04:55am EST
FILE PHOTO: The word

(Reuters) - Anti-inflammatory colchicine will be tested as a possible COVID-19 treatment in one of the world's biggest trials, the study website posted on Friday, the latest effort to repurpose existing medicines to fight the pandemic.

The RECOVERY trial, which is the world's largest clinical trial of treatments for patients hospitalised with COVID-19, will randomly allocate at least 2,500 patients recruited to receive colchicine, which is used as a treatment for gout.

"Colchicine is an attractive drug to evaluate in the RECOVERY trial as it is very well understood, inexpensive and widely available," SAID Oxford University Professor Peter Horby, who is co-chief investigator for the trial.

Colchicine costs about $124 for 30 capsules on the drugs.com website.

The scientists behind the trial said inflammation plays a major role in COVID-19 and treatment with dexamethasone, another anti-inflammatory drug, has already shown that it can reduce deaths in the most severely ill patients.

Earlier this month, one of Britain's biggest trials also evaluated painkiller aspirin as a possible treatment for COVID-19, assessing whether it might reduce the risk of blood clots in people with the disease.

Other treatments being tested in the RECOVERY trial include common antibiotic azithromycin and the Regeneron antibody cocktail that was used to treat U.S. President Donald Trump's COVID-19 symptoms.

(Reporting by Muvija M and Yadarisa Shabong in Bengaluru; Editing by David Goodman and Josephine Mason)

© Reuters 2020
Latest news "Economy & Forex"
08:12aCENTRAL PEOPLE GOVERNMENT OF PEOPLE RE : China's 2020 public health spending surges despite fiscal revenue drop
08:11aWall Street expects Tesla's deliveries to rise by at least 50% in 2021
08:09aWall St. heads for mixed start, eyes GDP, short-selling
08:06aIMF says fiscal support needed until recovery takes hold
08:06aCISCO : Going Beyond Cybersecurity & Facing World Challenges
08:05aS.African regulator awards Eskom additional 6 billion rand revenue
08:05aFig Linens and Home Updates Website to Better Serve Houseware and Home Design Shoppers
08:03aVersa SASE Awarded 2020 Cybersecurity Excellence Award
08:01aPIVOTREE : Announces Expansion of Cybersecurity Practice Led by New General Manager
07:59aUK court allows Abraaj founder's extradition to U.S.
Latest news "Economy & Forex"